Free Trial
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

GoodRx logo
$6.12
-0.26 (-4.08%)
(As of 10/31/2024 ET)

About GoodRx Stock (NASDAQ:GDRX)

Key Stats

Today's Range
$6.12
$6.39
50-Day Range
$6.21
$8.59
52-Week Range
$4.14
$9.26
Volume
599,631 shs
Average Volume
1.37 million shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.36
Consensus Rating
Moderate Buy

Company Overview

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

GoodRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
66th Percentile Overall Score

GDRX MarketRank™: 

GoodRx scored higher than 66% of companies evaluated by MarketBeat, and ranked 406th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    GoodRx has only been the subject of 4 research reports in the past 90 days.

  • Read more about GoodRx's stock forecast and price target.
  • Earnings Growth

    Earnings for GoodRx are expected to grow by 57.14% in the coming year, from $0.14 to $0.22 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GoodRx is -48.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GoodRx is -48.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    GoodRx has a PEG Ratio of 4.17. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    GoodRx has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GoodRx's valuation and earnings.
  • Percentage of Shares Shorted

    11.04% of the float of GoodRx has been sold short.
  • Short Interest Ratio / Days to Cover

    GoodRx has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in GoodRx has recently decreased by 0.78%, indicating that investor sentiment is improving.
  • Dividend Yield

    GoodRx does not currently pay a dividend.

  • Dividend Growth

    GoodRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.04% of the float of GoodRx has been sold short.
  • Short Interest Ratio / Days to Cover

    GoodRx has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in GoodRx has recently decreased by 0.78%, indicating that investor sentiment is improving.
  • News Sentiment

    GoodRx has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for GoodRx this week, compared to 7 articles on an average week.
  • Search Interest

    5 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,921.00 in company stock.

  • Percentage Held by Insiders

    Only 4.17% of the stock of GoodRx is held by insiders.

  • Percentage Held by Institutions

    63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GoodRx's insider trading history.
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

GDRX Stock News Headlines

GoodRx Unveils New E-commerce Platform, Launches with Opill®
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
GoodRx announces exclusive cash price for Qsymia
GoodRx Holdings Strengthens Board with New Appointment
See More Headlines

GDRX Stock Analysis - Frequently Asked Questions

GoodRx's stock was trading at $6.70 at the start of the year. Since then, GDRX stock has decreased by 6.7% and is now trading at $6.25.
View the best growth stocks for 2024 here
.

GoodRx Holdings, Inc. (NASDAQ:GDRX) announced its quarterly earnings data on Thursday, August, 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.01. The business's revenue for the quarter was up 5.7% on a year-over-year basis.

GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Top institutional shareholders of GoodRx include Raymond James & Associates (0.11%), Assenagon Asset Management S.A. (0.10%), Vontobel Holding Ltd. (0.02%) and Kesler Norman & Wride LLC (0.02%). Insiders that own company stock include Scott Wagner, Equity Vii LP Spectrum, Idea Men, Llc, Abdiel Capital Management, Llc, Trevor Bezdek, Babak Azad, Karsten Voermann and Andrew Slutsky.
View institutional ownership trends
.

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Data processing & preparation
Sub-Industry
Business Services
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
950
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.36
High Stock Price Target
$16.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+49.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$-8,870,000.00
Pretax Margin
-7.65%

Debt

Sales & Book Value

Annual Sales
$775.09 million
Cash Flow
$0.39 per share
Book Value
$1.93 per share

Miscellaneous

Free Float
363,630,000
Market Cap
$2.38 billion
Optionable
Optionable
Beta
1.37
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:GDRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners